Matthew Del Giudice
Fortune : 16 000 $ au 30/06/2026
Fortune : 16 000 $ au 30/06/2026
Matthew Paul Del Giudice is currently an Independent Director at MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc., both positions starting in 2024.
Formerly, the role was Head-General Overnight Emergency Radiologist at The Cleveland Clinic Foundation from 2021 to 2022.
Education includes undergraduate studies at the University of Illinois At Urbana–Champaign and a doctorate from Stritch School of Medicine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2026 | 12 500 ( 0,04% ) | 16 000 $ | 30/06/2026 | |
| 12/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 13/03/2024 |
| TELOMIR PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/08/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Corporate Officer/Principal | 01/05/2022 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Stritch School of Medicine
Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national